Drug Profile
Doxorubicin eosomes - Eos Biosciences
Alternative Names: Doxorubicin eosomes; Eos-001Latest Information Update: 14 Jan 2022
Price :
$50
*
At a glance
- Originator Eos Biosciences
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; ERBB-3 receptor modulators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Solid tumours
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Breast-cancer(Second-line therapy or greater) in USA (IV, Injection)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Solid-tumours(Second-line therapy or greater) in USA (IV, Injection)
- 17 Oct 2017 The U.S. Patent and Trademark Office issues U.S. Patent No. 9 789 201 for doxorubicin eosomes for Breast cancer